CGT environmental health and safety

16 August 2022
Advanced Therapy Medicinal Products

The rapidly expanding field of cell and gene therapies (CGT) could revolutionize curative treatments. Regulatory guidance has been developed to address manufacturing guidelines and CMC specifications for CGT drug products, but occupational health and safety guidelines for manufacturing CGT products have been lacking. For example, there is no ‘universal’ toxicological or potent compound classification or risk assessment scheme for CGT manufacturing processes.

This is why BioPhorum’s CGT environmental health and safety (EHS) and biosafety team was created to bring together biopharmaceutical industry leaders. It aims to develop best practices for personal and environmental safety when conducting CGT research or clinical and commercial manufacturing.

One of the team’s outputs is an article called Environmental Health and Biosafety Risk Assessment Guidance for Commercial-Scale Cell and Gene Therapy Manufacturing, which was published in Applied Biosafety: Journal of ABSA International.

The article aims to identify best practices, improve risk controls, and help regulatory agencies develop guidance for environmental and biosafety risk assessment for commercial-scale CGT manufacturing. It includes a risk assessment template highlighting the complexity of commercial-scale manufacturing, the areas to assess, the potential questions to ask, and which other parties may input to the risk assessment.

We spoke to two subject matter experts about the article and risk template and how they have used them in their work.

Summarize the landscape of this area

“EHS is a pretty well established discipline in our industry,” said Simon Godwin, Head of Gene Therapy Technical Operations at Sanofi and one of the authors of the article. “But with these new cell and gene therapy modalities, there are unique challenges in establishing EHS systems that provide the appropriate level of control for the operator, facility, and environments. The challenge is associated with the use of human origin materials in manufacturing (e.g., cell lines) where the biosafety risk profile is case-by-case and is impacted by sourcing, testing, and control of manufacturing.”

He added, “There is also a very diverse portfolio of genetic medicines and delivery platforms all intended to provide persistent and enduring therapeutic benefit, to which the long-term safety is yet to be realized. To this end, the HSE challenges for such dynamic and diverse biological entities cannot be standardized and managed under a universal safety data sheet. As such, it requires a directed biosafety risk assessment tool that enables the site to establish its own safety practices commensurate to the risk profile of its products and processes.”

Godwin explained that, like many other organizations, Sanofi had been challenged to find a balance between the corporate need to move fast and be more flexible, against having more safety, control, containment, and established practices.

This is why working with BioPhorum has been useful as the article and template help us calibrate as an industry and work together to establish best practices based on our combined and shared experiences.
Simon Godwin, Head of Gene Therapy Technical Operations at Sanofi

How did you use the BioPhorum article and template?

Ashley Holland, a safety specialist for Trinity Consultants supporting AstraZeneca Gaithersburg SHE, said its team used the template as a guide while designing its cell therapy lab. “We had a good idea of which projects would be assigned to the lab, and the template helped us ask questions about these projects and the hazards they presented. From there, we were able to update the lab’s design with additional control measures.”

She added that a concern during the design process was whether there were any ‘open’ steps. However, working with the scientists, the team identified the full process and where there was a potential for open steps. Section 4 ‘Process operations and control’ of the template fed into the questions asked by the team.

“At the time, the design phase was a fluid process,” Holland said. “So Section 6 ‘Facilities, equipment and utilities’ was a useful guide. When we met with the team, I asked similar questions about operating space, bearing in mind how materials would be transported. Section 10.0 ‘Storage, shipping and distribution’ was helpful in this step.”

Her team found Sections 6 through 12 ‘Emergency response’ were the most helpful in the design phase because they covered each aspect of the actual operation.

“While Sanofi already has an established EHS process,” said Godwin, “the BioPhorum template helped us ratify what we were doing. And because it was published in a reputable journal, it gave the whole thing more kudos.”

How did you apply the BioPhorum recommendations?

“During the design phase, we used the template as guidance and consulted with the site’s biosafety expert, Kimberly DiGiandomenico – Director SHE-Research & Animal Safety and an author of the Applied Biosafety article,” explained Holland. “At the time, we only used the template. After that, however, we adopted some BioPhorum recommendations, such as those on employee gowning and PPE, sanitization via vapor phase hydrogen peroxide (VHP), facility design with ballroom and ‘batch-dedicated’ rooms, and employee training.”

What lessons did you learn from going through this process?

“My overall takeaway from this process is that it is good to ask these questions during the design phase,” suggested Holland. “That’s when we have the most opportunity to make changes and plan ahead for topics such as those on training and admin controls. It’s also critical to consider future projects coming to the facility, not just what is scheduled. For us, projects in the pipeline have the opportunity to be moved to the facility, so asking whether the design is fit for future projects is important to keep in mind.”

Godwin said it was a little early for him to discuss lessons learned from using the template. “But I imagine that in a year or so, we’ll be able to compare how we applied the template in our businesses, how we interpreted the questions, whether we looked at things in the same way, etc. Reviewing our experiences might lead to greater harmonization.”

He added that documents like the template are always ‘translated’, so the correct use of language was crucial. “We might use British English or American English – it’s still English, but we interpret words differently. So how we use and translate the template might depend on how we understand and manage the risks. We’re still learning, so those future conversations will be really important.”

What are the benefits of being part of BioPhorum?

“For me, it’s taking a novel and complex situation and pulling together a diverse community of people with the same mindset and goal of establishing a common way of working,” said Godwin. “The template allows industry to have a great dialog, which might lead to new regulations, systems, or standards that could be applied more broadly across the industry rather than just in our own companies.”

He said that this community approach to improving our industry and the safety of our staff is what BioPhorum brings to the table. “It lets me go back to my company and look at our systems and say, ‘They’re not good enough’, or ‘Yes, we’re doing a good job’. Of course, we can’t prevent all accidents, but if one does happen, we know that we’ve done everything possible to make it the safest system available.

“As we adapt to these new modalities, these conversations help me ask, are we on the right path? Are we thinking about this the right way? So one of the main things to come out of the risk assessment is the team’s wider conversation. That’s where lessons are being learned, as it helps us ask where we’re aligned with each other and where we’re not. That’s the power of BioPhorum.”

A view from industry on the implication of the new Annex 1 requirements on visual inspection process
Maine and Minnesota – the BioPhorum responses to US state PFAS consultations
BioPhorum Supply Partner has become Supply Resilience
BioPhorum’s sustainability ambition – let’s move out of the holding pattern
Building a resilient business means adopting water stewardship

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Resilience

Supply Resilience is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
A launchpad for an improved CGT outbound supply chain
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Building a resilient business means adopting water stewardship
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing